Skip to main content
SpringerLink
Log in

The orexin neurotransmitter system as a target for medication development for opioid use disorder

  • Hot Topics
  • Published:
Neuropsychopharmacology Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Huhn AS, Finan PH, Gamaldo CE, Hammond AS, Umbricht A, Bergeria CL, et al. Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Sci Transl Med. 2022;14:eabn8238.

    Article  CAS  PubMed  Google Scholar 

  2. Singh R, Biswas DA. Physiological role of orexin/hypocretin in the human body in motivated behavior: a comprehensive review. Cureus. 2023;15:e34009.

    PubMed  PubMed Central  Google Scholar 

  3. Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT, Eisch AJ, et al. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci. 2003;23:3106–3111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. James MH, Aston-Jones G. Orexin reserve: a mechanistic framework for the role of orexins (hypocretins) in addiction. Biol Psychiatry. 2022;92:836–844. https://doi.org/10.1016/j.biopsych.2022.06.027

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA

    A. S. Huhn & K. E. Dunn

Authors
  1. A. S. Huhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. E. Dunn
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Both authors contributed to the conceptualization, drafting, and final revision of this work and agree to be held accountable for all aspects of the work.

Corresponding author

Correspondence to K. E. Dunn.

Ethics declarations

Competing interests

In the past 3 years, KED has consulted or served as an advisor to study protocols with companies Mind Med, Inc. DemeRx, Cessation Therapeutics, and Indivior and has received funding through her university from the National Institute on Drug Abuse and Cure Addiction Now. ASH has consulted for Gilgamesh and received research funding from Indivior through his University.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huhn, A.S., Dunn, K.E. The orexin neurotransmitter system as a target for medication development for opioid use disorder. Neuropsychopharmacol. 49, 329–330 (2024). https://doi.org/10.1038/s41386-023-01679-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41386-023-01679-0

  • Springer Nature Switzerland AG

Search

Navigation